Zhao-qian S. Liu
87 Xiangya Road
Changsha, 410008, China
Changsha, 410008, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 200 publications
Corrigendum to "CSDE1 enhances genotoxic drug resistance in cancer by modulating RPA2 through the CSDE1-eIF3a regulatory complex" [Drug Resist. Updat. 81 (2025) 101249].
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: August 22, 2026
Succinylation in cancer immunotherapy: mechanisms, biomarkers, and therapeutic implications.
Journal: Frontiers in immunology
Published: January 23, 2026
A two-stage genome-wide association study to identify novel genetic loci associated with irAEs in lung cancer patients receiving PD-1/PD-L1 inhibitors.
Journal: Cancer letters
Published: July 20, 2025
Association of Erythrocyte-Related Indices with Immune-Related Adverse Events and Survival of Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: July 15, 2025
Association of Ion Concentration with Immune-Related Adverse Events and Prognosis in Lung Cancer Patients Treated with PD-1/PD-L1 Inhibitors.
Journal: Journal of Cancer
Published: June 30, 2025
Multi-omics and artificial intelligence for precision drug discovery and potential clinical applications.
Journal: Signal transduction and targeted therapy
Published: May 07, 2025
Corrigendum to "Elemene mitigates oxidative stress and neuronal apoptosis induced by cerebral ischemia-reperfusion injury through the regulation of glutathione metabolism" [J. Ethnopharmacol. (2025) 340 119166].
Journal: Journal of ethnopharmacology
Published: April 12, 2025
CSDE1 enhances genotoxic drug resistance in cancer by modulating RPA2 through CSDE1-eIF3a regulatory complex.
Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Published: February 16, 2025
Exploring the biological functions and disease implications of OSGINs: A journey from discovery to clinical relevance.
Journal: Biochemical pharmacology
Published: February 11, 2025
Editorial: Ovarian cancer targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more, volume II.
Journal: Frontiers in pharmacology
Published: December 28, 2024
Exploring metabolic reprogramming in esophageal cancer: the role of key enzymes in glucose, amino acid, and nucleotide pathways and targeted therapies.
Journal: Cancer gene therapy
Published: October 18, 2024
Last Updated: 09/26/2026